Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2007-12-24
pubmed:abstractText
Duffy binding protein (DBP) plays a critical role in Plasmodium vivax invasion of human red blood cells. We previously reported a single-chain antibody fragment (scFv) that was specific to P. vivax DBP (PvDBP). However, the stabilization and the half-life of scFvs have not been studied. Here, we investigated the effect of PEGylated scFvs on their biological activity and stability in vitro. SDS-PAGE analysis showed that three clones (SFDBII-12, -58, and -92) were formed as dimers (about 70 kDa) with PEGylation. Clone SFDBII-58 gave the highest yield of PEGylated scFv. Binding analysis using BIAcore between DBP and scFv showed that both SFDBII-12 and -58 were decreased approximately by two folds at the level of binding affinity to DBP after PEGylation. However, the SFDBII-92 clone still showed a relatively high level of binding affinity (KD=1.02 x 10(-7) M). Binding inhibition assay showed that PEGylated scFv was still able to competitively bind the PvDBP and play a critical role in inhibiting the interactions between PvDBP protein expressed on the surface of Cos-7 cells and Duffy receptor on the surface of erythrocytes. When both scFvs and their PEGylated counterparts were exposed to trypsin, scFv was completely degraded only after 24 h, whereas 35% of PEGylated scFvs remained intact, maintaining their stability against the proteolytic attack of trypsin until 72 h. Taken together, these results suggest that the PEGylated scFvs retain their stability against proteolytic enzymes in vivo, with no significant loss in their binding affinity to target antigen, DBP.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1017-7825
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1670-4
pubmed:meshHeading
pubmed-meshheading:18156783-Animals, pubmed-meshheading:18156783-Antibodies, Protozoan, pubmed-meshheading:18156783-Antibody Affinity, pubmed-meshheading:18156783-Antigens, Protozoan, pubmed-meshheading:18156783-COS Cells, pubmed-meshheading:18156783-Cell Line, pubmed-meshheading:18156783-Cercopithecus aethiops, pubmed-meshheading:18156783-Electrophoresis, Polyacrylamide Gel, pubmed-meshheading:18156783-Erythrocytes, pubmed-meshheading:18156783-Humans, pubmed-meshheading:18156783-Immunoglobulin Fragments, pubmed-meshheading:18156783-Kinetics, pubmed-meshheading:18156783-Plasmodium vivax, pubmed-meshheading:18156783-Polyethylene Glycols, pubmed-meshheading:18156783-Protozoan Proteins, pubmed-meshheading:18156783-Receptors, Cell Surface, pubmed-meshheading:18156783-Recombinant Proteins, pubmed-meshheading:18156783-Surface Plasmon Resonance, pubmed-meshheading:18156783-Trypsin
pubmed:year
2007
pubmed:articleTitle
Effects of PEGylated scFv antibodies against Plasmodium vivax duffy binding protein on the biological activity and stability in vitro.
pubmed:affiliation
Department of Malariology, Paik Institute for Clinical Research, Inje University College of Medicine, Busan, Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't